Male Vitality
Provider-led hormone therapy for men's wellness.
TRT or Enclomiphene (lab-guided)Optional: PT-141Optional: NAD+
Sexual wellness therapy
PT-141 (Bremelanotide / Vyleesi), Central Sexual Wellness Therapy
Vyleesi (bremelanotide) is FDA-approved for premenopausal women with HSDD. Off-label and compounded use in men and other indications is physician-supervised.
PT-141 works differently from every other sexual wellness therapy you may have encountered. PDE5 inhibitors like sildenafil (Viagra) and tadalafil (Cialis) act peripherally to improve blood flow. PT-141 (bremelanotide, marketed as Vyleesi) acts centrally in the brain, activating melanocortin receptors in neural circuits that govern sexual desire and arousal.
For women with hypoactive sexual desire disorder (HSDD), the FDA-approved indication, and for some men with psychogenic erectile dysfunction or libido issues not responsive to PDE5 inhibitors, the distinction matters.
What it is
About this therapy
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide analog of α-melanocyte-stimulating hormone (α-MSH). It activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly in hypothalamic and arcuate nucleus circuits that regulate sexual motivation and arousal.
FDA approved Vyleesi in June 2019, making it the second FDA-approved drug for premenopausal women with HSDD (after flibanserin in 2015). Unlike flibanserin, which is taken daily, Vyleesi is used on demand, administered as a subcutaneous injection approximately 45 minutes before anticipated sexual activity.
Off-label use in men is offered at Genesis Longevity as an adjunct for psychogenic erectile dysfunction and libido disorders in men who have not responded to PDE5 inhibitors or prefer a central mechanism. This indication is not FDA-approved. Compounded intranasal PT-141 is also off-label.
How it works
Mechanism of action
PT-141 activates MC3R and MC4R receptors in the central nervous system, triggering dopaminergic signaling along pathways involved in motivation, arousal, and sexual behavior.
Central versus peripheral. PDE5 inhibitors (sildenafil, tadalafil, vardenafil) relax penile smooth muscle through a vascular mechanism, amplifying the nitric oxide signal that occurs with sexual stimulation. They do not address desire. PT-141 targets the neural circuits upstream of desire itself, which is why it may help patients who are psychologically inhibited, emotionally disconnected from arousal, or not responding to vascular-level interventions.
This mechanism also explains the primary side effects: melanocortin receptors in the brainstem mediate nausea, and facial flushing occurs from peripheral MC1R activation.
Conditions and use cases
Where this therapy may fit
FDA-approved.
- Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women, characterized by persistently low sexual desire that causes personal distress, not attributable to another medical condition, medication, or relationship issue.
Off-label, physician discretion, not FDA-approved.
- Male erectile dysfunction, particularly psychogenic ED or cases where PDE5 inhibitors have been inadequate. Approximately 34 percent response vs. 9 percent placebo in select male populations.
- Low libido in men, when the issue is desire rather than vascular function.
Expected timeline
What to expect over a care cycle
Week 0 to 2
First doses, on-demand
Onset within 45 minutes to 2 hours post-injection. Effect duration approximately 2 to 4 hours (half-life ~2.7 hours). Provider monitors blood pressure response.
Week 2 to 4
Tolerance review
Nausea and flushing patterns reviewed. Eating before injection, dose titration, or adjunctive antiemetic can be discussed. PT-141 does not accumulate over time.
Month 1 to 3
Use cadence
Maximum 1 dose per 24 hours and 8 doses per month per Vyleesi labeling. Compounded intranasal cadence is provider-determined.
Month 3 to 6
Skin and BP review
With chronic use, focal hyperpigmentation can occur from MC1R activation. Provider reviews any skin changes and BP at 3 to 6 months.
Stacks that include this
Designed into Male Vitality and She Thrives stacks
She Thrives
Designed to support women's hormonal health and wellness.
HRT: Estrogen + Progesterone or TestosteroneOptional: GHK-Cu PeptideOptional: NAD+
Investment and access
How to access this therapy at Genesis
Genesis Longevity therapies are dispensed only after a complimentary consultation and Good Faith Exam. Schedule yours to receive a personalized plan.
Safety
Side effects and contraindications
Reported side effects
Common.
- Nausea, approximately 40 percent. The most frequent side effect, often transient. Eating before injection, lower dose titration, or adjunctive antiemetic can help.
- Flushing, 20 to 40 percent. Transient, typically face and upper chest.
- Headache, 10 to 40 percent.
- Injection site reactions.
Less common.
- Transient blood pressure elevation, typically resolves within 12 hours (average +6/4 mmHg, up to +27/21 mmHg in some patients).
- Vomiting, dizziness.
Chronic use concern.
- Focal hyperpigmentation. MC1R activation with repeated dosing can cause localized skin darkening, typically on the face, gums, or breasts. Reversible upon discontinuation.
Contraindications and patient selection
Per FDA labeling and clinical guidelines.
- Uncontrolled hypertension. PT-141 causes transient BP elevation and is contraindicated in uncontrolled hypertension.
- Cardiovascular disease, history of MI, stroke, or unstable angina.
- Concurrent nitrates, absolute contraindication, risk of dangerous BP drop.
- Pregnancy and breastfeeding.
- Hypersensitivity to bremelanotide.
Frequently asked
Frequently asked questions
PDE5 inhibitors (Viagra, Cialis) act peripherally to enhance blood flow to genital tissue in response to stimulation. PT-141 acts centrally in the brain to enhance desire and arousal before stimulation. For patients whose primary issue is desire rather than vascular response, the distinction is clinically meaningful.
Yes, off-label. Studies in male populations with PDE5 inhibitor-refractory ED show approximately 34 percent response vs. 9 percent placebo in select populations. It is not FDA-approved for male ED but is used off-label under provider supervision.
Melanocortin receptors (MC4R) in the brainstem and hypothalamus mediate nausea. Nausea from PT-141 is typically transient, occurring in the first 1 to 2 hours after injection. Eating before injection, dose adjustment, or using an antiemetic such as ondansetron can reduce it.
The compounded intranasal form is not FDA-approved and has not undergone the same clinical-trial testing as Vyleesi. Bioavailability via intranasal route differs from subcutaneous. It is an option under provider supervision but carries the uncertainties of any compounded vs. branded comparison.
Hormone therapy (estrogen, testosterone, progesterone) addresses libido loss driven by hormonal deficiency. PT-141 addresses desire at the neural / receptor level and does not change hormone levels. For women with both hormonal deficiency and HSDD, both approaches may be complementary. A provider evaluation determines the primary driver.
Sources
Citations & references
- [1]FDA, Vyleesi (bremelanotide) approval documents and prescribing information. Source
- [2]Boston Medical Group, PT-141 mechanism and benefits overview. Source
- [3]Enavvi, PT-141 / bremelanotide clinical guide for physicians. Source
- [4]Boston Medical Group, PT-141 safety and warnings. Source
- [5]Men's Reproductive Health, PT-141 for men: a new drug for ED. Source
Status & disclosures
- FDA status
- Vyleesi (bremelanotide 1.75 mg SC autoinjector) is FDA-approved for premenopausal women with HSDD. Off-label use in men and compounded intranasal forms are not FDA-approved.
- Off-label men's use
- Genesis Longevity offers PT-141 off-label for men's libido and psychogenic ED contexts. Patients sign informed consent for off-label use.
- Cardiovascular caution
- PT-141 produces transient blood pressure elevation. Contraindicated in uncontrolled hypertension, cardiovascular disease, and concurrent nitrate use.
- Compounded forms
- Compounded intranasal PT-141 is dispensed by licensed 503A pharmacies under physician prescription. Bioavailability and dosing differ from Vyleesi.
Next step
Considering PT-141 for desire and arousal support?
Schedule a private consultation with a Genesis provider.
Or keep reading: Or visit the Sexual Wellness hub